



3415A 3 Ave NW, Calgary, Alberta, T2N 0M4, Canada

**Patient Name:** Patient, Name**Specimen ID (SID):** 25-001-0000**DOB:** 01-Jan-2000**PHN:** AB 0000000**Reason for Testing:** -**Relevant Medications:** -**External SID:** 123456789**Doctor:** Dr. Doctor**Report Date:** 12-Mar-2025**Specimen Type:** Plasma**Date/Time Collected:** 01-Jan-2025 / 00:00**Specimen Source:** MitogenDx**Complement Profile Panel****Laboratory Developed Test (LDT)**

Analyte	Results	Reference Interval†	Units
<b>CLASSICAL PATHWAY INITIATION</b>			
C1q	25.2	16.7 - 59.7	µg/ml
<b>LECTIN PATHWAY INITIATION</b>			
Mannose-Binding Lectin	9640 <b>HIGH</b>	109 - 4011	ng/ml
<b>CLASSICAL &amp; LECTIN PATHWAYS C3 CONVERTASE</b>			
C2	2516 <b>HIGH</b>	135 - 1587	ng/ml
C4	108	55 - 187	µg/ml
C4b	19.1 <b>HIGH</b>	2.2 - 18.0	µg/ml
<b>ALTERNATIVE PATHWAY C3 CONVERTASE</b>			
Adipsin	> 6660 <b>HIGH</b>	483 - 3933	ng/ml
Factor B	75.5	65 - 212	µg/ml
<b>MAJOR COMPLEMENT EFFECTOR</b>			
C3	55.6	10 - 161	µg/ml
C3b/iC3b	191 <b>HIGH</b>	15 - 122	µg/ml
<b>TERMINAL PHASE</b>			
C5	13.5	4.5 - 16.4	µg/ml
C5a	541 <b>HIGH</b>	0 - 460	pg/ml
<b>REGULATORY FACTORS</b>			
Factor H	93.5 <b>LOW</b>	105 - 251	µg/ml
Factor I	15.8	5.7 - 34.9	µg/ml

**Sample Comments:**

-

**Results Interpretation:**

These results indicate elevated levels of Mannose-Binding Lectin, C2, C4b, C3b/iC3b, and C5a, which may suggest an active complement pathway response, potentially reflecting ongoing inflammation or immune activation. The moderate high level of C5 may also support this interpretation. Conversely, the low level of Factor H could imply a reduced regulatory capacity within the complement system, which may contribute to dysregulation.

**Disclaimer:**

The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.

***In vitro* complement activation is likely to occur if samples are not stored and transported appropriately.**

**Reviewed by:** DP**Eve Technologies Corporation is a CLIA certified High Complexity International Laboratory**

† Reference intervals estimated by data-mining ≥400 PLASMA samples drawn from both healthy and pathological subjects.